

DAFTAR PUSTAKA

1. Novalia V. 2023. Kanker serviks. GALENICAL: Jurnal Kedokteran dan Kesehatan Mahasiswa Malikussaleh Vol.2 No.1 Februari 2023
2. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. *Chin J Cancer Res.* 2020 Dec 31;32(6):720-728. doi: 10.21147/j.issn.1000-9604.2020.06.05. PMID: 33446995; PMCID: PMC7797226.
3. Mahendra, et al. 2022. Profil Penderita Kanker Serviks Berdasarkan Stadium Di RSUP Prof. Dr. I.G.N.G Ngoerah Denpasar Bali Periode 1 Januari 2022-1 Januari 2023.
4. Hasan DI, Enaba MM, Abd El-Rahman HM, El-Shazely S. Apparent diffusion coefficient value in evaluating types, stages and histologic grading of cancer serviks. *Egypt J Radiol Nucl Med [Internet].* 2015;46(3):781–9. Available from: <https://www.sciencedirect.com/science/article/pii/S0378603X15000753>
5. Abd elsalam SM, Mokhtar O, Adel L, Hassan R, Ibraheim M, Kamal A. Impact of diffusion weighted magnetic resonance imaging in diagnosis of cervical cancer. *Egypt J Radiol Nucl Med.* 2020;51(1)
6. Fujii S, Iwata N, Inoue C, Mukuda N, Fukunaga T, Ogawa T, (2017). *Volume Measurement by Diffusion-Weighted Imaging in Cervical Cancer.* *Yonago Acta Med.* Jun; 60(2): 113–118
7. Chen H-H, Meng W-Y, Li R-Z, Wang Q-Y, Wang Y-W, Pan H-D, et al. Potential prognostic factors in progression-free survival for patients with cervical cancer. *BMC Cancer.* 2021 May;21(1):531.
8. Pirog E C. 2017. Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus – Positive and Human Papillomavirus–Negative Tumors. *Artikel.* 141 : 1653-1667.
9. Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. *J Neurosurg.* 2004 May;100(5):835–41.
10. Dolciami M, Canese R, Testa C, Pernazza A, Santangelo G, Palaia I, et al. The contribution of the 1H-MRS lipid signal to cervical cancer prognosis: a preliminary study. *Eur Radiol Exp.* 2022;6(1):1–9.

11. Iqbal Z, Albuquerque K, Chan KL. Magnetic Resonance Spectroscopy for Cervical Cancer: Review and Potential Prognostic Applications. *Cancers* (Basel). 2024 Jun 5;16(11):2141. doi: 10.3390/cancers16112141. PMID: 38893260; PMCID: PMC11171343.
12. Na JH et al. Localized In Vivo 1H MRS (Proton Magnetic Resonance Spectroscopy) for Histologic Type of the Cervical Cancer. *Korean J Obstet Gynecol.* 1998 Jun;41(6):1606-1612.
13. Nott J, Bonney AE, Pickering JD, Simpson NAB, 2016. The structure and function of the cervix during pregnancy. Elsevier. *Translational Research in Anatomy* 2(2016)1-7
14. Moore KL, Dalley AF, Agur AMR. 2014. Moore clinically oriented anatomy. Edisi ke-7. Baltimore: Lippincott Williams & Wilkins.
15. Komite Penanggulangan Kanker Nasional (KPKN). Kementerian Kesehatan Republik Indonesia; 2017. Panduan Penatalaksanaan Kanker Serviks.
16. Graff, D.V., 2001. Female Reproductive System. In: *Human Anatomy*. 6th ed. McGraw-Hill, 735.
17. Hiralal K, 2013. Chapter 01 Anatomy of female Reproductive Organ. DC Dutta 's Textbook of Obstetrics
18. Prendiville W, Sankaranarayanan R. Colposcopy and Treatment of Cervical Precancer. Lyon (FR): International Agency for Research on Cancer; 2017. PMID: 33689255.
19. IARC group. Chapter 1: An introduction to the anatomy of the uterine serviks. *Colposc Treat Cerv Intraepithelial Neoplasia A Beginner's Man.* 2015;1–12. Mcitos 2008
20. Mcintosh N. Cervical Cancer Prevention Guidleine for Low Resource Settings [Internet]. 2008. 2–4 p. Available from: <https://screening.iarc.fr/doc/CeCaPfullmanual.pdf>
21. WHO. *Comprehensive Cervical Cancer Control.* Geneva. 2014;366–78.
22. Fowler JR, Maani E V, Dunton CJ, Gasalberti DP, Jack BW, Network IH. *Cervical Cancer.* 2024;
23. World Health Organization. *Comprehensive cervical cancer prevention and control: a healthier future for girls and women WHO GUIDANCE NOTE WHO Library Cataloguing-in-Publication Data.* World Heal Organ [Internet]. 2020;12. Available from: www.who.int/about/licensing/
24. Manini I, Montomoli E. *Epidemiology and prevention of Human Papillomavirus.*

- Ann Ig. 2018;30(4 Supple 1):28–32.
25. Ghosh I, Mandal R, Kundu P, Biswas J. Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical Neoplasia. *J Clin Diagn Res.* 2016 Feb;10(2):XE01–6. Zhang S 2020
 26. Habtemariam LW, Zewde ET, Simegn GL. Serviks Type and Cervical Cancer Classification System Using Deep Learning Techniques. *Med Devices (Auckl).* 2022;15:163–76.
 27. Kuhn L, Denny L. The time is now to implement HPV testing for primary screening in low resource settings. *Prev Med (Baltim).* 2017 May;98:42–4.
 28. Paulina RE, Andi Y. 2019. Patogenesis Human Papillomavirus (HPV) pada Kanker Serviks. *Jurnal Biotek Medisiana Indonesia Vol.8.1.* 2019; Hal.23-32
 29. Arini PP: Karsinoma Serviks: Gambaran Radiologi dan Terapi Radiasi. *CDK-285/ vol. 47 no. 4 th.* 2020
 30. Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. *Geburtshilfe Frauenheilkd.* 2021;81(10):1145–53.
 31. Maniar KP, Wei J-J. Pathology of Cervical Carcinoma. *Glob Libr Women's Med.* 2017;(August).
 32. Hu S, Zhao X, Zhang Y, Qiao Y, Zhao F. Interpretation of “WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.” Vol. 101, *National Medical Journal of China.* 2021. 2653–2657 p.
 33. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: Utility of microscopic features in predicting patient outcome. *Head Neck Pathol.* 2009;3(3):186–94.
 34. Jenkins D. Histopathology and cytopathology of cervical cancer. *Dis Markers.* 2007;23(4):199–212.
 35. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the serviks uteri: 2021 update. *Int J Gynecol Obstet.* 2021;155(S1):28–44.
 36. Gala FB, Gala KB, Gala BM. Magnetic Resonance Imaging of Uterine Serviks: A Pictorial Essay. *Indian J Radiol Imaging.* 2021;31(2):454–67.
 37. Mahajan M, Kuber R, Chaudhari K, Chaudhari P, Ghadage P, Naik R. MR imaging of carcinoma serviks. *Indian J Radiol Imaging.* 2013;23(3):247–52.
 38. Kaur H, Silverman PM, Iyer RB, Verschraegen CF, Eifel PJ, Charnsangavej

- C. Diagnosis, staging, and surveillance of cervical carcinoma. *AJR Am J Roentgenol.* 2003 Jun;180(6):1621–31 Shweel MA, et al. 2012)
39. Shweel MA, et al. 2012. Uterine Cervical Malignancy: Diagnostic Accuracy of MRI with Histopathologic Correlation. <https://clinicalimagingscience.org/doi:10.4103/2156-7514.99175>
 40. Mori, Takayuki et al. 2023. MRI characteristics for predicting histological subtypes in patients with uterine cervical adenocarcinoma. *European Journal of Radiology*, Volume 158, 110612
 41. Liyanage SH, Roberts CA, Rockall AG. MRI and PET scans for primary staging and detection of cervical cancer recurrence. *Womens Health (Lond Engl).* 2010 Mar;6(2):251–9. (De Boier et al, 2019).
 42. de Boer P, Mandija S, Werensteijn-Honingh AM, van den Berg CAT, de Leeuw AAC, Jürgenliemk-Schulz IM. Cervical cancer apparent diffusion coefficient values during external beam radiotherapy. *Phys imaging Radiat Oncol.* 2019 Jan;9:77–82.
 43. Kady, Choudhary, Tappouni, 2011. Accuracy of Apparent Diffusion Coefficient Value Measurement on PACS Workstation: A Comparative Analysis. *AJR* 2011; 196:W280–W284
 44. Yilmaz, E, et al. Diffusion-Weighted Imaging for the Discrimination of Benign and Malignant Breast Masses; Utility of ADC and Relative ADC. *Journal of the Belgian Society of Radiology.* 2018; 102(1): 24, pp. 1–6. DOI: <https://doi.org/10.5334/jbsr.1258>
 45. Ghardon, S.S.L., Hemida, R., Borg, M.A. et al. Correlative study between apparent diffusion coefficient value and grading of cervical cancer. *Egypt J Radiol Nucl Med* **53**, 170 (2022). <https://doi.org/10.1186/s43055-022-00850-9>
 46. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. *AJNR Am J Neuroradiol.* 2004 Feb;25(2):201–9.
 47. Jajodia A, Mahawar V, Chaturvedi A, Rao A, Singla R, Mitra S, et al. Role of ADC values in assessing clinical response and identifying residual disease post-chemo radiation in uterine cervix cancer. *Indian J Radiol Imaging.* 2019 Dec 31;29:404.
 48. Satta S, Dolciami M, Celli V, Di Stadio F, Perniola G, Palaia I, et al. Quantitative diffusion and perfusion MRI in the evaluation of endometrial cancer: validation with histopathological parameters. *Br J Radiol.* 2021

Sep;94(1125):20210054.

49. Fardanesh R, Marino MA, Avendano D, Leithner D, Pinker K, Thakur SB. Proton MR spectroscopy in the breast: technical innovations and clinical applications. *J Magn Reson Imaging*. 2019;50(4):1033–46.
50. Glunde K, Penet MF, Jiang L, Jacobs MA, Bhujwala ZM. Choline metabolism-based molecular diagnosis of cancer: An update. *Expert Rev Mol Diagn*. 2015;15(6):735–47.
51. Payne GS, et al, 2010. Evaluation of magnetic resonance diffusion and spectroscopy measurements as predictive biomarkers in stage 1 cervical cancer, *Gynecologic Oncology*, Volume 116, Issue 2, 2010. Pages 246-252, <https://doi.org/10.1016/j.ygyno.2009.09.044>. Roberto et al, 2015
52. Julià-Sapé M, Candiota AP, Arús C. Cancer metabolism in a snapshot: MRS(I). *NMR Biomed*. 2019;32(10):1–21.
53. De Silva SS, Payne GS, Thomas V, Carter PG, Ind TEJ, deSouza NM. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue. *NMR Biomed*. 2009 Feb;22(2):191–8.
54. Yao N, Li W, Xu G, Duan N, Yu G and Qu J (2023) Choline metabolism and its implications in cancer. *Front. Oncol.* 13:1234887. doi: 10.3389/fonc.2023.1234887
55. Dewi Anggraeni, F., Rahayu, R., Studi, P., Stikes, K., Achmad, J., Yogyakarta, Y., & Ringroad Barat, J. (2017a). Gambaran Karakteristik Wanita Yang Mengalami Kanker Serviks Di Rumah Sakit Umum Daerah (RSUD) Panembahan Senopati Bantul Yogyakarta .
56. Mekonnen AG, Mittiku YM. Early-onset of sexual activity as a potential risk of cervical cancer in Africa: A review of literature. *PLOS Glob Public Health*. 2023 Mar 22;3(3):e0000941. doi: 10.1371/journal.pgph.0000941. PMID: 36962975; PMCID: PMC10032528.
57. Andini DM, Lutfiasari D, 2021. The Correlation Between Marital Age and The Incidence of Cervical Cancer. DOI: <https://doi.org/10.53350/pjmhs211561509>
58. Sharma P, Pattanshetty SM. Sebuah studi tentang faktor risiko kanker serviks di antara pasien yang dirawat di rumah sakit perawatan tersier: studi kasus-kontrol. *Clin Epidemiol Global Health*. 2018;6(2):83–7. doi: 10.1016/j.cegh.2017.10.001.
59. Werneck, AO, Coelho-e-Silva, MJ, Padilha, CS, Ronque, ERV, Cyrino, ES,

- Szwarcwald, CL, & Silva, DR (2018). *Usia menarche dan risiko kanker di masa dewasa. Annals of Human Biology*, 1–4. doi:10.1080/03014460.2018.1470670
60. Dewi NIK, 2020. Hubungan usia menarche dengan kejadian lesi prakanker serviks di daerah perkotaan Indonesia (Analisis data penelitian penyakit tidak menular tahun 2016). Tesis FKUI
 61. Wu X, et al. A correlation study between cervical cancer and sex hormones. *Front Oncol*. 2024 Nov 29;14:1475052. doi: 10.3389/fonc.2024.1475052. PMID: 39678493; PMCID: PMC11638056.
 62. Roura E, et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. *PLoS One*. 2016 Jan 25;11(1):e0147029. doi: 10.1371/journal.pone.0147029. Erratum in: *PLoS One*. 2016 Mar 08;11(3):e0151427. doi: 10.1371/journal.pone.0151427. PMID: 26808155; PMCID: PMC4726518.
 63. Tekalegn Y, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. *Womens Health (Lond)*. 2022 Jan-Dec;18:17455065221075904. doi: 10.1177/17455065221075904. PMID: 35114865; PMCID: PMC8819811.
 64. Kuang, F., Ren, J., Zhong, Q. *dkk*. Nilai koefisien difusi nyata dalam penilaian kanker serviks. *Eur Radiol* **23**, 1050–1058 (2013). <https://doi.org/10.1007/s00330-012-2681-1>
 65. Ghani MA, Liao J, Eskander R, Mell L, Yusufaly T, Obrzut S. Imaging Biomarkers and Liquid Biopsy in Assessment of Cervical Cancer. *J Comput Assist Tomogr*. 2022 Sep-Oct 01;46(5):707-715. doi: 10.1097/RCT.0000000000001358. Epub 2022 Aug 16. PMID: 35995483; PMCID: PMC9474655.
 66. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. *Nat Rev Cancer*. 2011 Nov 17;11(12):835-48. doi: 10.1038/nrc3162. PMID: 22089420; PMCID: PMC4337883.



REKOMENDASI PERSETUJUAN ETIK

Nomor : 135/UN4.6.4.5.31/ PP36/ 2025

Tanggal: 24 Februari 2025

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH25020100	No Sponsor	
Peneliti Utama	dr. Rosani Amir	Sponsor	
Judul Peneliti	UJI DIAGNOSTIK ADC VALUE DAN CHOLINE PEAK MR SPECTROSCOPY TERHADAP TIPE HISTOPATOLOGI PADA PENDERITA KANKER SERVIKS PRETERAPI DI RS UNIVERSITAS HASANUDDIN		
No Versi Protokol	1	Tanggal Versi	10 Februari 2025
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 24 Februari 2025 sampai 24 Februari 2026	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

DAFTAR RIWAYAT HIDUP

Curriculum Vitae



Data Pribadi / Personal Details

Nama / *Name* : dr. Rosani Amir
Alamat / *Address* : Jl. Anoa No.4, Kota Baubau
Nomor Telepon / *Phone* : 082243421576
Email : rosani.amir27@gmail.com
Jenis Kelamin / *Gender* : Perempuan
Tanggal Kelahiran / *Date of Birth* : Ujung Pandang, 27 april 1989
Status Marital / *Marital Status* : Menikah
Warga Negara / *Nationality* : Indonesia
Agama / *Religion* : Islam
Nama Orang Tua / *Parent's Name* :
 Nama Ayah / *Father Name* : Amir Thayeb, BE (rahimahullah)
 Nama Ibu / *Mother Name* : St.Nuraeni
Pekerjaan Orang Tua / *Parent's Job* : Pekerjaan
 Ayah / *Father Job* : -
 Pekerjaan Ibu / *Mother Job* : -

Riwayat Pendidikan

Educational and Professional Qualification

Jenjang Pendidikan :

Education Information

Periode			Sekolah / Institusi / Universitas
1994	-	1995	TK Pembina Baraya
1995	-	2001	SDN KIP Baraya
2001	-	2004	SMPN 10 Makassar
2004	-	2007	SMAN 06 Makassar
2007	-	2013	Universitas Hasanuddin
2022	-	2025	PPDS-1 Radiologi Universitas Hasanuddin

Publikasi

Publication

Periode	Publikasi
2025	Nilai Diagnostik ADC Value MRI dan Choline Peak MR Spectroscopy Dengan Tipe Histopatologi Pada Penderita Kanker Serviks Preterapi di RS Universitas Hasanuddin

Simposium

Symposium

Periode	Simposium
2023	Workshop dan Symposium PIT PERAMI MALANG
2024	Update on Interventional Radiology Workshop
2024	Workshop Update Multimodality Imaging of Women and Musculoskeletal
2024	ISMRM mastering MRI Physics Reading Made simple

Demikian riwayat hidup ini saya buat dengan sebenar-benarnya.

Makassar, 8 Mei 2025



dr. Rosani Amir

